Simplex Trading’s Regencell Bioscience RGC Stock Holding History

Simplex Trading’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-217	Closed	-$3K	–	9825
2025 Q3	$3K	Buy	+217	New	+$3.11K	﹤0.01%	8550

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Simplex Trading's RGC Position: Q4 2025 in Review

Simplex Trading sold out of Regencell Bioscience (RGC) in Q4 2025, closing a stake of 217 shares — an estimated $3K sold.

Simplex Trading first reported a position in RGC in Q3 2025 and held it in 1 quarter. The position peaked at $3K in Q3 2025. 17 funds tracked by Wall St. Rank hold RGC as of Q4 2025.

Simplex Trading reported no remaining Regencell Bioscience position as of Q4 2025 after selling out during the quarter.
Simplex Trading sold 217 Regencell Bioscience shares in Q4 2025, an estimated $3K.
Simplex Trading first reported a position in Regencell Bioscience in Q3 2025 and held it in 1 quarter.
Simplex Trading's Regencell Bioscience position peaked at $3K in Q3 2025.
17 funds tracked by Wall St. Rank held Regencell Bioscience as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.